PRNAF — ALTERITY THERAPEUTICS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1131343 ·
Australia
Last close
$0.00
Market Cap
$11.96M
52W High
$0.01
52W Low
$0.00
ADV30
0
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 56,918,905 | 49,200,547 | 2,650,906 |
| Jun 2025 | — | — | — | — | 46,026,360 | 33,158,642 | 3,623,274 |
| Dec 2024 | — | — | — | — | 10,546,933 | 4,536,559 | 2,760,926 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-234,379,461
Inventory
—
Receivables
$6,842,493
ST Investments
$7,500,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,636,421
EBITDA
$-17,550,620
Free Cash Flow
$-10,609,269
Enterprise Value
$-37,139,140
Total Cash
$49,200,548
Total Debt
$98,449
Shares Out
10,875,416,329
Trailing EPS
$0.00
Book Value
$0.00
ROE
-47.0%
ROA
-32.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -12,333,683 | -12,147,828 | 46,026,360 | 3,623,274 | — | -11,451,248 |
| Jun 2024 | 0 | -19,402,317 | -19,123,464 | 19,223,743 | 5,425,686 | — | -12,605,824 |
| Jun 2023 | 0 | -14,368,225 | -13,806,515 | 27,317,636 | 4,504,727 | — | -20,035,837 |
| Jun 2022 | 0 | -15,137,322 | -12,847,061 | 41,362,611 | 5,894,020 | — | -12,337,274 |
| Jun 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KPRX | KIORA PHARMACEUTICALS INC | $11.97M | $2.70 | — |
| CALC | CalciMedica, Inc. | $12.01M | $0.76 | — |
| GOVX | GeoVax Labs, Inc. | $12.12M | $3.49 | — |
| PHIO | Phio Pharmaceuticals Corp. | $12.55M | $1.08 | — |
| APRE | Aprea Therapeutics, Inc. | $11.27M | $0.91 | — |
News headlines (Yahoo Finance, 1h cache)
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
2026-05-19 11:25 · Yahoo
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
2026-05-11 11:25 · Yahoo
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
2026-05-07 11:25 · Yahoo
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
2026-04-30 11:25 · Yahoo
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
2026-04-27 11:25 · Yahoo
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
2026-04-22 11:25 · Yahoo
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
2026-04-17 11:25 · Yahoo
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
2026-04-16 11:25 · Yahoo
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
2026-04-15 11:25 · Yahoo
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
2026-03-30 11:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.